Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.

PubMed  PubMed Central  Google Scholar 

Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics. 2016;10:103–17. https://doi.org/10.2147/btt.S87878.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marrone KA, Naidoo J, Brahmer JR. Immunotherapy for lung cancer: no longer an abstract concept. Semin Respir Crit Care Med. 2016;37(5):771–82. https://doi.org/10.1055/s-0036-1592298.

Article  PubMed  Google Scholar 

Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24. https://doi.org/10.1016/s0140-6736(16)31473-8.

Article  PubMed  Google Scholar 

Xiong W, Zhao Y, Du H, Guo X. Current status of immune checkpoint inhibitor immunotherapy for lung cancer. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.704336.

Article  PubMed  PubMed Central  Google Scholar 

Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21(5):821–33. https://doi.org/10.1111/resp.12789.

Article  PubMed  Google Scholar 

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, et al. The Society for Immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):75. https://doi.org/10.1186/s40425-018-0382-2.

Article  PubMed  PubMed Central  Google Scholar 

Gd C Jr, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non–small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol. 2021. https://doi.org/10.1200/jco.21.02885.

Article  Google Scholar 

Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, et al. Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency Assessment Report - Keytruda. 2019. https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0060-epar-assessment-report-variation_en.pdf. (Accessed 29/03/2023).

Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol. 2020;15(4):499–519.

Article  CAS  PubMed  Google Scholar 

Mino-Kenudson M, Le Stang N, Daigneault JB, Nicholson AG, Cooper WA, Roden AC, et al. The International Association for the Study of Lung Cancer Global Survey on programmed death-ligand 1 testing for NSCLC. J Thorac Oncol. 2021;16(4):686–96. https://doi.org/10.1016/j.jtho.2020.12.026.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu HL, Jin. 2022 Chinese Society of Clinical Oncology (CSCO) NSCLC guidelines 2022.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Nonsmall cell lung cancer. Version 2.2023. 2023 February 17, 2023.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.

Article  CAS  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. https://doi.org/10.1200/jco.18.00149.

Article  CAS  PubMed  Google Scholar 

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/s0140-6736(16)00561-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74. https://doi.org/10.1158/1078-0432.Ccr-13-3271.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saxena P, Singh PK, Malik PS, Singh N. Immunotherapy alone or in combination with chemotherapy as first-line treatment of non-small cell lung cancer. Curr Treat Opt Oncol. 2020;21(8):69. https://doi.org/10.1007/s11864-020-00768-2.

Article  Google Scholar 

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. https://doi.org/10.1016/s0140-6736(18)32409-7.

Article  CAS  PubMed  Google Scholar 

Wu Y-L, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non–small-cell lung cancer: KEYNOTE-042 China study. Int J Cancer. 2021;148(9):2313–20. https://doi.org/10.1002/ijc.33399.

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005.

Article  CAS  PubMed  Google Scholar 

Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer. J Clin Oncol. 2020;38(14):1505–17. https://doi.org/10.1200/jco.19.03136.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51. https://doi.org/10.1056/NEJMoa1810865.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657–69. https://doi.org/10.1016/j.jtho.2020.06.015.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.

Article  CAS  PubMed  Google Scholar 

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–75. https://doi.org/10.1001/jamaoncol.2018.3039.

Article  PubMed  PubMed Central  Google Scholar 

Kreke JE, Schaefer AJ, Roberts MS. Simulation and critical care modeling. Curr Opin Crit Care. 2004;10(5):395–8.

Article  PubMed  Google Scholar 

Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force–2. Med Decis Making. 2012;32(5):678–89.

Article  PubMed  Google Scholar 

Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Med Decis Making. 2012;32(5):667–77.

Article  PubMed  Google Scholar 

Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–310.

Article  PubMed  Google Scholar 

Davis S, Stevenson M, Tappenden P, Wailoo A. Cost-effectiveness modelling using patient-level simulation. National Institute for Health and Care Excellence (NICE); 2014.

Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MM, Pechlivanoglou P. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Making. 2018;38(3):400–22.

Article  PubMed  PubMed Central  Google Scholar 

Rutter CM, Zaslavsky AM, Feuer EJ. Dynamic microsimulation models for health outcomes: a review. Med Decis Making. 2011;31(1):10–8.

Article  PubMed  Google Scholar 

Liu GWJ, Wu J, et al. China guidelines for pharmacoeconomic evaluations 2020. Beijing: China Market Press; 2020.

Google Scholar 

Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833–42. https://doi.org/10.1016/S2214-109X(23)00162-6.

Article  CAS  PubMed  Google Scholar 

Dongmei LIN, Shun LU. Chinese Expert Consensus on Standards of PD-L1 Immunohistochemistry testing for non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2020;23(9):733–40. https://doi.org/10.3779/j.issn.1009-3419.2020.101.43.

Paces W, Ergon E, Bueche E, Young GD, Adisetiyo V, Luengo C, et al. A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer. Sci Rep. 2022;12(1):9745. https://doi.org/10.1038/s41598-022-12697-1.

Article